A study evaluating outcomes of patients who receive a haploidentical HSCT with the post-transplantation cyclophosphamide regimen with or without BPX-501

Trial Profile

A study evaluating outcomes of patients who receive a haploidentical HSCT with the post-transplantation cyclophosphamide regimen with or without BPX-501

Planning
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Rivogenlecleucel (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2017 New trial record
    • 13 Mar 2017 According to a Bellicum Pharmaceuticals media release, this trial will be supported by the Cancer Prevention and Research Institute of Texas (CPRIT) and will initiate by year-end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top